Display options
Cite
Schmidt IM, Srivastava A, Sabbisetti V, et al. Plasma Kidney Injury Molecule 1 in CKD: Findings From the Boston Kidney Biopsy Cohort and CRIC Studies. Am J Kidney Dis. 2021;doi: 10.1053/j.ajkd.2021.05.013.
Schmidt, I. M., Srivastava, A., Sabbisetti, V., McMahon, G. M., He, J., Chen, J., Kusek, J. W., Taliercio, J., Ricardo, A. C., Hsu, C. Y., Kimmel, P. L., Liu, K. D., Mifflin, T. E., Nelson, R. G., Vasan, R. S., Xie, D., Zhang, X., Palsson, R., Stillman, I. E., Rennke, H. G., Feldman, H. I., Bonventre, J. V., Waikar, S. S. (2021). Plasma Kidney Injury Molecule 1 in CKD: Findings From the Boston Kidney Biopsy Cohort and CRIC Studies. American journal of kidney diseases : the official journal of the National Kidney Foundation, . https://doi.org/10.1053/j.ajkd.2021.05.013
Schmidt, Insa M, et al. "Plasma Kidney Injury Molecule 1 in CKD: Findings From the Boston Kidney Biopsy Cohort and CRIC Studies." American journal of kidney diseases : the official journal of the National Kidney Foundation vol. (2021). doi: https://doi.org/10.1053/j.ajkd.2021.05.013
Schmidt IM, Srivastava A, Sabbisetti V, McMahon GM, He J, Chen J, Kusek JW, Taliercio J, Ricardo AC, Hsu CY, Kimmel PL, Liu KD, Mifflin TE, Nelson RG, Vasan RS, Xie D, Zhang X, Palsson R, Stillman IE, Rennke HG, Feldman HI, Bonventre JV, Waikar SS. Plasma Kidney Injury Molecule 1 in CKD: Findings From the Boston Kidney Biopsy Cohort and CRIC Studies. Am J Kidney Dis. 2021 Jun 25; doi: 10.1053/j.ajkd.2021.05.013. Epub 2021 Jun 25. PMID: 34175376; PMCID: PMC8709877.
Copy Download .nbib Format: NLM
Share it on

Am J Kidney Dis. 2021 Jun 25; doi: 10.1053/j.ajkd.2021.05.013. Epub 2021 Jun 25.

Plasma Kidney Injury Molecule 1 in CKD: Findings From the Boston Kidney Biopsy Cohort and CRIC Studies.

American journal of kidney diseases : the official journal of the National Kidney Foundation

Insa M Schmidt, Anand Srivastava, Venkata Sabbisetti, Gearoid M McMahon, Jiang He, Jing Chen, John W Kusek, Jonathan Taliercio, Ana C Ricardo, Chi-Yuan Hsu, Paul L Kimmel, Kathleen D Liu, Theodore E Mifflin, Robert G Nelson, Ramachandran S Vasan, Dawei Xie, Xiaoming Zhang, Ragnar Palsson, Isaac E Stillman, Helmut G Rennke, Harold I Feldman, Joseph V Bonventre, Sushrut S Waikar,

Affiliations

  1. Section of Nephrology, Department of Medicine, Boston University School of Medicine, Boston Medical Center Boston, Massachusetts; Renal Division, Brigham & Women's Hospital, Harvard Medical School Boston, Massachusetts.
  2. Division of Nephrology and Hypertension, Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  3. Renal Division, Brigham & Women's Hospital, Harvard Medical School Boston, Massachusetts.
  4. Department of Epidemiology and Medicine, Tulane University School of Public Health and Tropical Medicine, Tulane University School of Medicine, New Orleans, Louisana.
  5. Department of Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
  6. Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
  7. Division of Nephrology, Department of Medicine, University of Illinois, Chicago, Illinois.
  8. Division of Nephrology, University of California San Francisco School of Medicine, San Francisco, California.
  9. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
  10. Chronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona.
  11. Section of Preventive Medicine and Epidemiology, Boston University Boston, Massachusetts.
  12. Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  13. Department of Pathology, Beth Israel Deaconess Medical Center Boston, Massachusetts.
  14. Pathology Department, Brigham & Women's Hospital, Boston, Massachusetts.
  15. Section of Nephrology, Department of Medicine, Boston University School of Medicine, Boston Medical Center Boston, Massachusetts; Renal Division, Brigham & Women's Hospital, Harvard Medical School Boston, Massachusetts. Electronic address: [email protected].

PMID: 34175376 PMCID: PMC8709877 DOI: 10.1053/j.ajkd.2021.05.013

Abstract

RATIONALE & OBJECTIVE: Plasma kidney injury molecule 1 (KIM-1) is a sensitive marker of proximal tubule injury, but its association with risks of adverse clinical outcomes across a spectrum of kidney diseases is unknown.

STUDY DESIGN: Prospective, observational cohort study.

SETTING & PARTICIPANTS: 524 individuals enrolled into the Boston Kidney Biopsy Cohort (BKBC) Study undergoing clinically indicated native kidney biopsy with biopsy specimens adjudicated for semiquantitative scores of histopathology by 2 kidney pathologists and 3,800 individuals with common forms of chronic kidney disease (CKD) enrolled into the Chronic Renal Insufficiency Cohort (CRIC) Study.

EXPOSURE: Histopathologic lesions and clinicopathologic diagnosis in cross-sectional analyses, baseline plasma KIM-1 levels in prospective analyses.

OUTCOMES: Baseline plasma KIM-1 levels in cross-sectional analyses, kidney failure (defined as initiation of kidney replacement therapy) and death in prospective analyses.

ANALYTICAL APPROACH: Multivariable-adjusted linear regression models tested associations of plasma KIM-1 levels with histopathologic lesions and clinicopathologic diagnoses. Cox proportional hazards models tested associations of plasma KIM-1 levels with future kidney failure and death.

RESULTS: In the BKBC Study, higher plasma KIM-1 levels were associated with more severe acute tubular injury, tubulointerstitial inflammation, and more severe mesangial expansion after multivariable adjustment. Participants with diabetic nephropathy, glomerulopathies, and tubulointerstitial disease had significantly higher plasma KIM-1 levels after multivariable adjustment. In the BKBC Study, CKD in 124 participants progressed to kidney failure and 85 participants died during a median follow-up time of 5 years. In the CRIC Study, CKD in 1,153 participants progressed to kidney failure and 1,356 participants died during a median follow-up time of 11.5 years. In both cohorts, each doubling of plasma KIM-1 level was associated with an increased risk of kidney failure after multivariable adjustment (hazard ratios of 1.19 [95% CI, 1.03-1.38] and 1.10 [95% CI, 1.06-1.15] for BKBC and CRIC, respectively). There was no statistically significant association of plasma KIM-1 levels with death in either cohort.

LIMITATIONS: Generalizability and unmeasured confounding.

CONCLUSIONS: Plasma KIM-1 is associated with underlying tubulointerstitial and mesangial lesions and progression to kidney failure in 2 cohort studies of individuals with kidney diseases.

Copyright © 2021. Published by Elsevier Inc.

References

  1. Am J Kidney Dis. 2016 Sep;68(3):371-80 - PubMed
  2. Diabetes Care. 2015 Jun;38(6):1130-7 - PubMed
  3. Am J Physiol Renal Physiol. 2002 Dec;283(6):F1326-36 - PubMed
  4. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S148-53 - PubMed
  5. J Am Soc Nephrol. 2014 Oct;25(10):2177-86 - PubMed
  6. J Am Soc Nephrol. 2018 Aug;29(8):2213-2224 - PubMed
  7. Nephrol Dial Transplant. 2016 Sep;31(9):1460-70 - PubMed
  8. Nephrol Dial Transplant. 2020 Feb 1;35(2):265-273 - PubMed
  9. J Am Soc Nephrol. 2017 Sep;28(9):2786-2793 - PubMed
  10. Diabetes Res Clin Pract. 2014 Mar;103(3):516-21 - PubMed
  11. J Am Soc Nephrol. 2005 Apr;16(4):1126-34 - PubMed
  12. Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2141-2149 - PubMed
  13. Nephrol Dial Transplant. 2018 Nov 1;33(11):1950-1959 - PubMed
  14. JAMA. 2015 Sep 1;314(9):884-94 - PubMed
  15. J Biomed Inform. 2009 Apr;42(2):377-81 - PubMed
  16. Clin Transl Sci. 2008 Dec;1(3):200-8 - PubMed
  17. Microvasc Res. 2009 Jan;77(1):4-7 - PubMed
  18. Diabetes Obes Metab. 2018 Aug;20(8):1988-1993 - PubMed
  19. J Am Soc Nephrol. 2020 May;31(5):1067-1077 - PubMed
  20. Nat Biotechnol. 2010 May;28(5):478-85 - PubMed
  21. Kidney Int. 2018 May;93(5):1198-1206 - PubMed
  22. Am J Physiol Renal Physiol. 2004 Mar;286(3):F552-63 - PubMed
  23. Am J Kidney Dis. 2020 Feb;75(2):187-194 - PubMed
  24. J Pathol. 2007 Jun;212(2):209-17 - PubMed
  25. Scand J Clin Lab Invest Suppl. 2008;241:78-83 - PubMed
  26. Endocrine. 2012 Feb;41(1):82-8 - PubMed
  27. Kidney Int. 2011 Feb;79(4):464-70 - PubMed
  28. J Am Soc Nephrol. 2014 Jul;25(7):1545-53 - PubMed
  29. N Engl J Med. 2014 Jul 3;371(1):58-66 - PubMed
  30. Diabetes Care. 2011 Apr;34(4):975-81 - PubMed
  31. Kidney Int. 2017 Jan;91(1):196-203 - PubMed
  32. J Am Soc Nephrol. 2015 Jan;26(1):220-9 - PubMed
  33. J Biol Chem. 1998 Feb 13;273(7):4135-42 - PubMed
  34. Kidney Int. 2002 Jul;62(1):237-44 - PubMed
  35. Ann Intern Med. 2009 May 5;150(9):604-12 - PubMed
  36. Kidney Int. 2017 Jul;92(1):258-266 - PubMed
  37. Kidney Int. 2011 May;79(10):1113-8 - PubMed
  38. Am J Transl Res. 2019 Mar 15;11(3):1219-1229 - PubMed
  39. Am J Kidney Dis. 2014 Jul;64(1):49-56 - PubMed
  40. Am J Kidney Dis. 2012 Dec;60(6):904-11 - PubMed
  41. Am J Kidney Dis. 2012 Aug;60(2):250-61 - PubMed
  42. Clin J Am Soc Nephrol. 2020 Mar 6;15(3):349-358 - PubMed
  43. Diabetes Res Clin Pract. 2012 Jul;97(1):71-6 - PubMed
  44. J Clin Invest. 2013 Sep;123(9):4023-35 - PubMed
  45. Kidney Int. 2016 Feb;89(2):459-67 - PubMed
  46. Kidney Int. 2012 Jul;82(2):172-83 - PubMed
  47. J Am Soc Nephrol. 2010 Mar;21(3):536-42 - PubMed
  48. Diabetologia. 2015 Jan;58(1):188-98 - PubMed
  49. Clin J Am Soc Nephrol. 2015 Nov 6;10(11):1956-63 - PubMed

Publication Types

Grant support